Reason for drop…SkinBioTherapeutics!16 Feb 2026 08:57
Investing.com -- SkinBioTherapeutics PLC (LON:SBTX) on Monday said it has launched an investigation into former CEO Stuart Ashman following allegations of material financial misrepresentation that will force a 17% reduction in the company’s reported 2025 revenue.
The British skin-health group confirmed it will reverse £770,000 in royalty income, a move expected to significantly widen operating losses and leave fiscal 2026 results well below market expectations.
SkinBioTherapeutics said new information received late on Feb. 13 cast "significant doubt" on the validity of the royalty income, which it believes was included due to a "potential misrepresentation" by former CEO Stuart Ashman.
Ashman, who was suspended on Feb. 13 pending an investigation into his conduct, has since resigned. The company informed him of the allegations on Feb. 15 and has reported its findings to auditors.
The revenue reversal will push the company’s adjusted EBITDA for fiscal 2025 to a loss of £1.17 million from a reported loss of £410,000, with operating losses widening to £1.47 million. The adjustments remain subject to auditor confirmation.
SkinBioTherapeutics warned that results for the year ending June 30, 2026, will be "significantly below current market expectations" of £6.2 million in revenue and £700,000 in adjusted EBITDA.
The company said it has a "robust cash position" of £2.92 million as of Feb. 13, down from £4.78 million at the end of June 2025.
Non-Executive Chairman Martin Hunt has temporarily assumed the role of Executive Chairman while the company searches for an interim CEO and a permanent replacement.
The board said it has launched a broader investigation to review financial reporting and operations across all group businesses, though it believes the incident is isolated.
The company said contracts with key partners remain sound and its two subsidiaries, Dermatonics and Bio-Tech Solutions, are trading as expected.
SkinBioTherapeutics develops products based on its SkinBiotix technology for skincare and skin health applications.